Concepedia

DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY

Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan Kehler, Jeanelle McSurdy-Freed, Joel W. Proksch, Brian R. Smith

Drug Metabolism and Disposition · 2004 · 43 citations · 20 references

DOI

References

20

Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery

Joseph W. Polli, Stephen A. Wring, Joan E. Humphreys et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 658 citations

Active secretion and enterocytic drug metabolism barriers to drug absorption

Vincent J. Wacher, Laurent Salphati, Leslie Z. Benet · Advanced Drug Delivery Reviews · 1996 · 310 citations

, , +6

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

Shirley M. Tsunoda, R VELEZ, L VONMOLTKE et al. · Clinical Pharmacology & Therapeutics · 1999 · 256 citations

In Vitro Substrate Identification Studies for P-glycoprotein-Mediated Transport: Species Difference and Predictability of in Vivo Results

Masayo Yamazaki, William Neway, Tomoyuki Ohe et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 237 citations

Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery

Leslie Z. Benet, Chi-Yuan Wu, Mary F. Hébert et al. · Journal of Controlled Release · 1996 · 198 citations

, , +7